IRIDEX (NASDAQ:IRIX) Major Shareholder Shih-Yao David Lin Purchases 50,000 Shares of Company Stock

Posted by Brian Himes on Oct 8th, 2026

IRIDEX Corporation (NASDAQ:IRIX – Get Free Report) major shareholder Shih-Yao David Lin acquired 50,000 shares of IRIDEX stock in a transaction dated Thursday, June 5th. The shares were acquired at an average price of $0.99 per share, with a total value of $49,500.00. Following the completion of the transaction, the insider owned 570,184 shares of the company’s stock, valued at approximately $564,482.16. This trade represents a 9.61% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

IRIDEX Price Performance

Shares of IRIX stock opened at $0.88 on Thursday. IRIDEX Corporation has a 12-month low of $0.61 and a 12-month high of $1.65. The firm has a market capitalization of $15.46 million, a price-to-earnings ratio of -4.40 and a beta of 0.67. The business has a 50 day simple moving average of $0.73 and a 200 day simple moving average of $0.95.

IRIDEX (NASDAQ:IRIX – Get Free Report) last announced its quarterly earnings results on Tuesday, August 18th. The medical equipment provider reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.06). The business had revenue of $12.57 million during the quarter, compared to the consensus estimate of $13.59 million. On average, equities analysts anticipate that IRIDEX Corporation will post -0.12 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded shares of IRIDEX from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, October 2nd. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $3.00.

Read Our Latest Research Report on IRIX

More IRIDEX News

Here are the key news stories impacting IRIDEX this week:

Positive Sentiment: SEC disclosures show Lin made dozens of purchases totaling substantial share amounts, including transactions of 50,000 shares at $0.99, 40,114 shares at $1.00 and 80,000 shares at $1.00. The repeated buying and growing ownership stake may be interpreted as a sign of confidence in IRIDEX’s long-term prospects. IRIDEX major shareholder buys 50,000 shares
Positive Sentiment: The filings also include purchases at prices ranging from approximately $0.84 to $1.52, with several individual transactions valued between roughly $20,000 and $58,000. This broad pattern of buying, rather than a single isolated trade, likely attracted speculative interest in the thinly traded stock. IRIDEX major shareholder acquires stock
Neutral Sentiment: Investors should note that most purchases occurred weeks or months earlier, from March through June and in prior reporting periods; the disclosures are new, but the buying itself is not. The reports therefore provide sentiment support rather than evidence of a new operating development or immediate improvement in revenue and earnings.
Neutral Sentiment: Trading in IRIX was temporarily halted under a Limit Up-Limit Down (LULD) pause, indicating that the stock’s rapid move exceeded permitted price bands. This highlights significant volatility and the potential for sharp reversals once trading resumes.

Institutional Trading of IRIDEX

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Renaissance Technologies LLC boosted its holdings in IRIDEX by 6.7% during the first quarter. Renaissance Technologies LLC now owns 396,627 shares of the medical equipment provider’s stock worth $401,000 after buying an additional 25,067 shares in the last quarter. Weber Capital Management LLC ADV bought a new position in shares of IRIDEX in the second quarter valued at $206,616. Perkins Capital Management Inc. increased its holdings in shares of IRIDEX by 33.9% in the first quarter. Perkins Capital Management Inc. now owns 55,300 shares of the medical equipment provider’s stock valued at $56,000 after buying an additional 14,000 shares in the last quarter. Thompson Davis & CO. Inc. lifted its position in shares of IRIDEX by 66.5% during the 1st quarter. Thompson Davis & CO. Inc. now owns 47,444 shares of the medical equipment provider’s stock valued at $48,000 after acquiring an additional 18,944 shares during the last quarter. Finally, United Capital Financial Advisors LLC acquired a new stake in shares of IRIDEX during the 2nd quarter valued at $41,000. 20.10% of the stock is owned by institutional investors and hedge funds.

About IRIDEX

(Get Free Report)

IRIDEX Corporation (NASDAQ: IRIX) develops and sells ophthalmic laser systems and related delivery devices used in the treatment of eye diseases. Its products are designed primarily for ophthalmologists treating glaucoma and retinal disorders, including diabetic retinopathy and other conditions affecting the retina.

The company’s portfolio includes laser systems such as the Cyclo G6 glaucoma laser platform and the IQ series of retinal photocoagulation lasers. IRIDEX also offers specialized probes and other delivery devices, including MicroPulse and transscleral cyclophotocoagulation technologies, which are intended to provide targeted treatment while limiting exposure to surrounding tissue.

Founded in 1989 and headquartered in Mountain View, California, IRIDEX serves eye-care professionals through a combination of direct sales and distributor relationships in the United States and international markets.